JPRN-UMIN000002310已完成未知
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis. - Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients. (GBCRG-2surg-01)
Gunma Breast Cancer Research Group 2 surgery0 个研究点目标入组 90 人开始时间: 2009年8月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients who received previous endocrine therapy or chemotherapy 2)Severe drug allergic history 3)Inflammatory breast cancer 4)Bilateral breast cancer in same time 5)Severe complications 6)Active double cancer 7)Inflammation with fever up 8)Neurological problem 9)Pleural effusion or pericardial effusion 10)Symptomatic brain metastasis 11)Pregnancy 12)Severe edema 13)Interstitial lung disease, pulmonary fibrosis 14)Psychiatric disease 15)Doctors decision for excluion 16)Low risk in St. Gallen Conferences 2007 17)16 weeks or more after operation
研究者
相似试验
已完成
3 期
eoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: Evaluation of biological, clinical and imaging markers of tumour response.Cancer - BreastBreast CancerACTRN12605000588695Monash Health180
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
已完成
不适用
eo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcergastric cancerJPRN-UMIN000015632Department of Frontier Surgery, Graduate school of Medicine, Chiba University20
已完成
1 期
Combination of chemotherapy with docetaxel / cisplatin / fluorouracil (DCF) and autologous gamma/delta T cell transfer therapy for esophageal cancer.Esophageal cancerJPRN-UMIN000008097The University of Tokyo Hospital20
已完成
2 期
Docetaxel and S-1 as adjuvant chemotherapy for pathological stage II, IIIA, IIIB gastric cancerPathological stage II, IIIa, or IIIb gastric cancerJPRN-UMIN000000857Dept. of Surgery and Science, Kyushu University20